Medico Remedies Board of Directors
Get the latest insights into the leadership at Medico Remedies. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Haresh Mehta | Chairman |
| Harshit Mehta | Managing Director |
| Rishit Mehta | Whole Time Director |
| Rita Mehta | Non Independent & Non Executive Director |
| Deepak Vekaria | Non Executive Independent Director |
| Bharat Rathod | Non Executive Independent Director |
| Deepesh Shah | Non Executive Independent Director |
| Kunal Tushar Vora | Non Executive Independent Director |
| Anuj Mody | Non Executive Independent Director |
| Vidhi Ankit Shah | Company Secretary & Compliance Officer |
| Maheshkumar Darji | Executive Director |
Medico Remedies FAQs
The board at Medico Remedies consists of experienced professionals, including Haresh Mehta, Harshit Mehta, and others, overseeing the company’s strategic and corporate governance.
Directors at Medico Remedies are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Haresh Mehta is the current chairman at Medico Remedies.
Executive directors at Medico Remedies are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Medico Remedies adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Medico Remedies, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
